Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Columbia Labs Says FDA Panel Declines To Recommend Approval Of Preterm Birth Gel

RELATED NEWS
Trade CBRX now with 
1/20/2012 5:19 PM ET

Columbia Laboratories, Inc. (CBRX: Quote), and Watson Pharmaceuticals, Inc. (WPI: Quote) announced that the Advisory Committee for Reproductive Health Drugs of the U.S. Food and Drug Administration or FDA declined to recommend approval of progesterone vaginal gel 8% for the reduction of risk of preterm birth in women with short uterine cervical length at the mid-trimester of pregnancy.

Both the companies noted that while panel members agreed that progesterone vaginal gel 8% is safe, the panel stated that more information is needed to support approval.

The company added that as the FDA will consider recommendations of the Committee, the final decision regarding the approval of the product rests solely with the FDA. The FDA's Division of Reproductive and Urologic Products is expected to take action on Columbia's New Drug Application or NDA by February 26, 2012.

Further, the Committee evaluated data submitted by Columbia to the FDA in its New Drug Application, which includes data from two Phase III clinical trials.

The company stated that one of these trials, the PREGNANT study, showed that women with a short uterine cervical length as measured by transvaginal ultrasound between 19 and <24 weeks of gestation who were treated with progesterone vaginal gel 8% had a significantly lower risk of preterm birth before 33 weeks gestation compared to those who were treated with placebo. This study included women with and without a prior history of preterm birth.

Register
To receive FREE breaking news email alerts for Columbia Laboratories Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Data-storage products maker NetApp Inc. said Tuesday after the markets closed that its fourth quarter profit fell 4% from last year, hurt mainly by higher operating expenses even as revenue grew slightly. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Analog Devices, Inc. said that its second quarter profit rose slightly from last year, helped mainly by lower income tax expenses even as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations. However, the company forecast third quarter revenue and earnings below analysts' current consensus estimates. While buying interest was relatively subdued, stocks moved modestly higher over the course of the trading day on Tuesday. The strength on the day offset the weakness seen in the previous session, with the Dow and the S&P 500 reaching new record closing highs. The major averages gave back some ground in late-day trading but remained in positive territory.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.